Directory
>
Axel Hoos
Axel Hoos
Member, Board of Trustees | GSK
Boston, Massachusetts, United States
Axel Hoos
Summary
Dr. Axel Hoos is a distinguished leader in the biotechnology sector, currently serving as the CEO of Scorpion Therapeutics, a pioneering company focused on Precision Oncology 2.0. With a rich background in oncology, he has held significant roles at GlaxoSmithKline, where he was instrumental in advancing the field of immuno-oncology. His experience spans various leadership positions, including serving on the board of multiple organizations dedicated to cancer research and immunotherapy. Dr. Hoos is also a co-founder of Imugene and has a strong academic background with an MD and a PhD in molecular oncology. He has been recognized for his contributions to the development of groundbreaking cancer therapies, including the first checkpoint inhibitor. His commitment to innovation and patient-centered medicine drives his work in transforming cancer treatment. Outside of his corporate roles, he actively participates in non-profit organizations aimed at improving global health.
Axel Hoos
Work Experience
Member, Board of Trustees at
The Alacrity Group
Present
Director, Board of Directors at
NextPoint Therapeutics, Inc.
March 2023 - Present
Chief Executive Officer at
Scorpion Therapeutics, Inc.
July 2021 - Present
Scientific Advisory Board Member at
Cancer Research Institute (CRI)
January 2014 - Present
Former SVP and R&D Governance Chair, Oncology at
GSK
February 2012 - Present
Member, Board of Trustees at
The Alacrity Group
January 2006 - Present
Co-Director Cancer Immunotherapy Consortium at
Cancer Research Institute (CRI)
January 2004 - Present
Director, Board of Directors at
Tcr2 Therapeutics Inc.
April 2020 - June 2023
Co-Founder, and Non-Executive Director at
Imugene Limited
January 2012 - November 2021
Senior Vice President, R&D Governance Chair, and Therapeutic Area Head Oncology at
GSK
January 2018 - July 2021
Chairman, Board of Trustees at
The Alacrity Group
January 2014 - December 2020
Senior Vice President, Therapeutic Area Head, Oncology R&D at
GSK
January 2015 - January 2018
Vice President, Immuno-Oncology at
GSK
January 2012 - January 2015
Global Medical Lead, Immunology/Oncology at
Bristol Myers Squibb
January 2005 - January 2012
Senior Director, Clinical Development at
Agenus
January 2001 - January 2005
Axel Hoos
Education
January 2008 - January 2009
Memorial Sloan Kettering Cancer Center (MSKCC), Fellowship
January 1999 - January 2001
Technical University of Munich , Residency
January 1997 - January 1999
DKFZ German Cancer Research Center , Phd
January 1993 - January 1997
January 1990 - January 1997
Frequently Asked Questions about Axel Hoos
What is Axel Hoos email address?
Axel Hoos's primary email address is *****@cancerresearch.org. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Axel Hoos work for?
Axel Hoos is a Member, Board of Trustees at GSK, a company specializing in Pharmaceutical & Medicine Manufacturing.
Where Axel Hoos graduated from?
Axel Hoos holds a degree in Business Administration And Management, General from Harvard Business School.
How can I directly contact Axel Hoos?
To contact Axel Hoos directly, you can use the email address *****@cancerresearch.org. Complete contact information is available upon registration with Muraena.
Is Axel Hoos an immigrant?
Yes, Axel Hoos is an immigrant and currently based in United States
Who is Axel Hoos?
Dr. Axel Hoos is a distinguished leader in the biotechnology sector, currently serving as the CEO of Scorpion Therapeutics, a pioneering company focused on Precision Oncology 2.0. With a rich background in oncology, he has held significant roles at GlaxoSmithKline, where he was instrumental in advancing the field of immuno-oncology. His experience spans various leadership positions, including serving on the board of multiple organizations dedicated to cancer research and immunotherapy. Dr. Hoos is also a co-founder of Imugene and has a strong academic background with an MD and a PhD in molecular oncology. He has been recognized for his contributions to the development of groundbreaking cancer therapies, including the first checkpoint inhibitor. His commitment to innovation and patient-centered medicine drives his work in transforming cancer treatment. Outside of his corporate roles, he actively participates in non-profit organizations aimed at improving global health.
Axel`s contact details
*****@cancerresearch.org
***********@gsk.com
*********@bms.com
*********@sabin.org
Colleagues
Medical Executive Director - Oncology Russia and Cis
President, North America
Bank of America, VP, Network Automation & Telemetry, Global Technology
Non-Executive Director, Member Of Audit And Risk, Remuneration Committees
Director, State Government Relations-New England & NY
Managing Partner
VP Development and Oncology Portfolio